Insulin Target Cells-based In Vitro Screening Service

Insulin Target Cells-based In Vitro Screening Service

Your Best Partner for Insulin Target Cells-based In Vitro Screening

Combining high-throughput screening with metabolomics and lipidomics, CD BioGlyco provides our clients with high-quality In Vitro Glycobiology Disease Model Screening services. Our specialized Glycobiology Disease Model Development services have gained recognition from clients all over the world. Our researchers rapidly measure insulin secretion and synthesis through high-throughput screening strategies. In addition, we also provide screening services for specific targets such as genes, enzymes, bioactive factors, and biomarkers.

  • Cell culture and treatments
    • CD BioGlyco has many years of experience in cell culture and processing. We provide insulin target cells including but not limited to INS-1 cells, HIT-T15 cells, Min6 cells, and RIN cells. At the appropriate site, our lab provides accurate induced differentiation services.
    • Our lab uses automated automated fluorescence microscopy to capture cell images with ultrastructural resolution. We provide comprehensive phenotyping at the single-cell level through morphological characterization.
  • High-throughput screening
    • CD BioGlyco provides high-throughput screening strategies for in vitro screening of insulin target cells. We provide accurate quantitative insulin analysis services by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) analysis.
    • Based on a multi-well automated detection mode, we provide a candidate gene evaluation service for siRNA. Moreover, we identify new biological targets or bioactive compounds by chemical libraries.
    • We use enzyme-linked immunosorbent assays (ELISA) for high-efficiency analysis of secreted hormones or specific proteins such as insulin or C-peptide.
    • In modified genetically engineered cells, we use immunofluorescence microscopy or luciferase-based methods for secretion measurements.

In vitro screening strategies based on insulin target cells. (CD BioGlyco)

Publication

Technology: MALDI-TOF-MS, ELISA

Journal: Cells

Published: 2023

IF: 7.666

Results: In this work, researchers established a new mouse β-cell model, Min6, based on automated glucose-stimulated insulin secretion (GSIS) and MALDI-TOF-MS, which identifies novel compounds or genes involved in β-cell function and quantifies insulin secretion in response to glucose. In total, the researchers screened siRNAs for common β-cell genes and 1600 compounds, then analyzed them to obtain several factors that regulate insulin secretion or inhibition.

Fig.1 Quantification of insulin secretion in Min6 cells.Fig.1 Measurement of insulin secretion from Min6 cells through MALDI-TOF-MS. (Delannoy, et al., 2023)

Applications

  • Insulin target cells-based in vitro screening can be used for inhibitor or modulator development.
  • Insulin target cells-based in vitro screening identifies new potential drugs and targets that positively affect beta cell function and insulin secretion.
  • Insulin target cells-based in vitro screening can be used for novel target identification.
  • Insulin target cells-based in vitro screening regulates molecules secreted by other peptide hormones, such as glucagon-like peptide 1 (GLP-1).

Advantages of Us

  • The data reports delivered by our professional staff include compound-induced cell physiology, multilevel toxicity, and potential molecular targets in addition to routine information.
  • The high throughput screening we offer allows comprehensive screening of small molecules for cellular regulatory activity.
  • Based on project characteristics, we offer a full range of services including model design, construction, screening, and data processing services.

CD BioGlyco has advanced screening strategies and a well-trained team to provide our clients with satisfactory screening services for glycobiological disease models. Please feel free to contact us.

Reference

  1. Delannoy, C.P.; et al. High-throughput quantitative screening of glucose-stimulated insulin secretion and insulin content using automated MALDI-TOF mass spectrometry. Cells. 2023, 12(6): 849.
This service is for Research Use Only, not intended for any clinical use.

Christmas 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0